Bartlett & CO. Wealth Management LLC Has $7.26 Million Position in Bristol Myers Squibb Company $BMY

Bartlett & CO. Wealth Management LLC lowered its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 11.8% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 134,602 shares of the biopharmaceutical company’s stock after selling 18,002 shares during the quarter. Bartlett & CO. Wealth Management LLC’s holdings in Bristol Myers Squibb were worth $7,260,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of BMY. Gateway Investment Advisers LLC boosted its holdings in shares of Bristol Myers Squibb by 10.0% in the third quarter. Gateway Investment Advisers LLC now owns 113,457 shares of the biopharmaceutical company’s stock valued at $5,117,000 after buying an additional 10,284 shares during the period. CWA Asset Management Group LLC boosted its holdings in shares of Bristol Myers Squibb by 25.9% in the third quarter. CWA Asset Management Group LLC now owns 150,359 shares of the biopharmaceutical company’s stock valued at $6,781,000 after buying an additional 30,909 shares during the period. Stephens Inc. AR boosted its position in shares of Bristol Myers Squibb by 13.5% during the third quarter. Stephens Inc. AR now owns 273,343 shares of the biopharmaceutical company’s stock worth $12,328,000 after buying an additional 32,476 shares during the period. Railway Pension Investments Ltd boosted its position in shares of Bristol Myers Squibb by 3.7% during the third quarter. Railway Pension Investments Ltd now owns 1,139,600 shares of the biopharmaceutical company’s stock worth $51,396,000 after buying an additional 40,300 shares during the period. Finally, Phoenix Financial Ltd. boosted its position in shares of Bristol Myers Squibb by 110.1% during the third quarter. Phoenix Financial Ltd. now owns 106,154 shares of the biopharmaceutical company’s stock worth $4,789,000 after buying an additional 55,624 shares during the period. Institutional investors and hedge funds own 76.41% of the company’s stock.

Insiders Place Their Bets

In related news, EVP David V. Elkins sold 30,000 shares of Bristol Myers Squibb stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the completion of the sale, the executive vice president directly owned 159,248 shares of the company’s stock, valued at approximately $9,820,824.16. This trade represents a 15.85% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 0.09% of the company’s stock.

Bristol Myers Squibb Stock Performance

NYSE BMY opened at $58.61 on Friday. The firm has a 50-day moving average of $59.78 and a 200-day moving average of $53.12. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.14 and a current ratio of 1.26. The stock has a market cap of $119.66 billion, a PE ratio of 16.99, a P/E/G ratio of 0.17 and a beta of 0.27. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $62.89.

Bristol Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). The company had revenue of $12.50 billion for the quarter, compared to analyst estimates of $12.24 billion. Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The business’s quarterly revenue was up 1.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.67 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, sell-side analysts anticipate that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, May 1st. Investors of record on Thursday, April 2nd will be issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 4.3%. The ex-dividend date of this dividend is Thursday, April 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 73.04%.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Cobenfy showing commercial momentum — grew to roughly $155M in 2025 and is outpacing peers, supporting upside potential from new indications. Does Cobenfy Have the Potential to Become a Top Drug for BMY?
• Positive Sentiment: New R&D collaboration with Oxford BioTherapeutics to discover next‑generation T‑cell engagers for solid tumors — expands BMS’s oncology pipeline and validates external discovery partnerships. Oxford BioTherapeutics Enters Strategic Collaboration with Bristol Myers Squibb…
• Positive Sentiment: Analyst support: Guggenheim reiterated a Buy rating, which can lend short-term confidence to the stock. Guggenheim Reiterates Buy Rating for Bristol Myers Squibb (NYSE:BMY)
• Neutral Sentiment: Dividend resilience noted — BMY highlighted as a recession‑resistant dividend stock, supporting income‑investor interest. 2 Recession Resistant Dividend Stocks to Buy Now While They’re Still Cheap
• Neutral Sentiment: Cantor Fitzgerald adjusted its price recommendation history (raised prior levels) but flagged Q1 catalysts are weak—mixed messaging that tempers conviction. Cantor Fitzgerald Lifts Bristol Myers (BMY) Price Target but Flags Weak Q1 Catalyst
• Neutral Sentiment: Macro note: BofA says many biopharma names are largely exempt from proposed pharma tariffs — a mild tailwind for the sector. Biopharma Stocks Largely Exempt From Pharma Tariffs, BofA Says
• Negative Sentiment: Near‑term revenue/earnings caution: a Zacks piece notes BMY’s YTD gains but warns generic erosion and the company’s 2026 sales outlook are reasons for investor caution. BMY Gains 10% Year to Date: Should You Buy, Sell or Hold the Stock?
• Negative Sentiment: Earnings risk: previews and analyst commentary expect a sizable Q1 earnings decline, which increases short‑term downside risk around the upcoming release. Bristol-Myers Squibb Earnings Preview: What to Expect
• Negative Sentiment: Some sell‑side adjustments show modestly lower price targets (Bank of America trimmed a target from $68 to $67; other outlets note PT shifts), signaling cautious near‑term sentiment. Benzinga

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on BMY shares. Citigroup upped their price objective on Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a “neutral” rating in a research report on Friday, February 6th. Cantor Fitzgerald upped their price objective on Bristol Myers Squibb from $45.00 to $54.00 and gave the stock a “neutral” rating in a research report on Wednesday. Royal Bank Of Canada initiated coverage on shares of Bristol Myers Squibb in a report on Tuesday, February 24th. They set a “sector perform” rating and a $60.00 target price for the company. Piper Sandler restated an “overweight” rating and set a $75.00 target price (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday, February 23rd. Finally, UBS Group restated a “buy” rating and set a $70.00 target price on shares of Bristol Myers Squibb in a report on Friday, March 6th. Nine research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $61.71.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.